Neurophet, a company specializing in artificial intelligence (AI) for the diagnosis and treatment of brain diseases, has set the final public offering price at 14,000 won.
Neurophet announced on the 14th that it has confirmed the public offering price at the upper end of the desired range (11,400 to 14,000 won) as a result of demand forecasting conducted for institutional investors from the 4th to the 10th. The public offering scale is 28 billion won, and the market capitalization after listing is 160.7 billion won.
A total of 2,444 institutions participated in this demand forecast, recording a competition rate of 1,087.6 to 1. It was found that 100% of the participating institutions proposed prices above the upper limit.
Neurophet is a company that develops and supplies software tools that precisely analyze brain MRI (magnetic resonance imaging) and PET (positron emission tomography) data based on AI technology. The company was founded in 2016 by co-CEO Jin-gil Bin and Dong-hyun Kim, who were researchers in brain science at the Gwangju Institute of Science and Technology (GIST).
Neurophet is scheduled to conduct subscription for general investors on the 15th and 16th. The listing date is July 25. Mirae Asset Securities is the underwriter for the listing.